AP2011005687A0 - Sustained release drug delivery system. - Google Patents

Sustained release drug delivery system.

Info

Publication number
AP2011005687A0
AP2011005687A0 AP2011005687A AP2011005687A AP2011005687A0 AP 2011005687 A0 AP2011005687 A0 AP 2011005687A0 AP 2011005687 A AP2011005687 A AP 2011005687A AP 2011005687 A AP2011005687 A AP 2011005687A AP 2011005687 A0 AP2011005687 A0 AP 2011005687A0
Authority
AP
ARIPO
Prior art keywords
delivery system
drug delivery
sustained release
release drug
sustained
Prior art date
Application number
AP2011005687A
Other languages
English (en)
Inventor
Madhu Rana
Subheet Jain
Pal Sing Hardevinder
Original Assignee
Bioplus Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplus Life Sciences Pvt Ltd filed Critical Bioplus Life Sciences Pvt Ltd
Publication of AP2011005687A0 publication Critical patent/AP2011005687A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2011005687A 2008-10-08 2009-10-08 Sustained release drug delivery system. AP2011005687A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2158MU2008 2008-10-08
PCT/IN2009/000562 WO2010041279A2 (en) 2008-10-08 2009-10-08 Sustained release drug delivery system

Publications (1)

Publication Number Publication Date
AP2011005687A0 true AP2011005687A0 (en) 2011-06-30

Family

ID=42101042

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005687A AP2011005687A0 (en) 2008-10-08 2009-10-08 Sustained release drug delivery system.

Country Status (14)

Country Link
US (2) US9622977B2 (pt)
EP (1) EP2349221A4 (pt)
JP (1) JP2012505203A (pt)
KR (1) KR20110069150A (pt)
CN (1) CN102307574A (pt)
AP (1) AP2011005687A0 (pt)
AU (1) AU2009301994B2 (pt)
BR (1) BRPI0914080A2 (pt)
CA (1) CA2739246A1 (pt)
EA (1) EA201170529A1 (pt)
IL (1) IL212195A0 (pt)
MX (1) MX2011003749A (pt)
WO (1) WO2010041279A2 (pt)
ZA (1) ZA201103240B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
CN102784203A (zh) * 2011-05-20 2012-11-21 上海凯宝药业股份有限公司 一种痰热清片剂及其制备方法
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US20150030683A1 (en) * 2012-02-18 2015-01-29 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
ITUB20150279A1 (it) * 2015-03-09 2016-09-09 S I I T S R L Servizio Int Imballaggi Termosaldanti Sistema flottante per la cura dei sintomi delle affezioni gastriche
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
CN105496982B (zh) * 2015-12-24 2018-10-19 广东药科大学 一种壳聚糖片剂及其制备方法
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US12263252B2 (en) 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
CN111302859A (zh) * 2020-03-27 2020-06-19 王世伟 一种新型土壤改良剂的制备和应用
CN115684514B (zh) * 2022-11-24 2024-04-26 则正(济南)生物科技有限公司 评价仿制药和原研药生物利用度的方法及其应用
CN121793948A (zh) * 2023-09-01 2026-04-03 豪夫迈·罗氏有限公司 用于制备半固体组合物的新颖方法及其用途
CN118496734B (zh) * 2024-06-04 2025-08-26 山东科技大学 一种用于严酷环境智能探测传感器的循环自修复智能防腐涂料的制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
ES2234139T3 (es) * 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
AP2002002410A0 (en) * 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
US20020119192A1 (en) * 2000-09-22 2002-08-29 Vishwanathan Narayanan Badri Controlled release formulations for oral administration
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6787234B2 (en) 2002-05-15 2004-09-07 Oms Investments, Inc. Triggered start products and processes for the production and use thereof
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US20040018559A1 (en) 2002-07-26 2004-01-29 Applera Corporation Size-exclusion ion-exchange particles
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
AU2006263337A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
JP4699896B2 (ja) 2005-12-28 2011-06-15 ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー 超音波プローブ保護用ブラケット及び超音波プローブ
BRPI0705072B8 (pt) * 2007-04-27 2021-05-25 Univ Estadual Campinas Unicamp grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form

Also Published As

Publication number Publication date
AU2009301994B2 (en) 2016-10-20
IL212195A0 (en) 2011-06-30
US20170165269A1 (en) 2017-06-15
CN102307574A (zh) 2012-01-04
EA201170529A1 (ru) 2012-01-30
WO2010041279A3 (en) 2010-07-01
WO2010041279A2 (en) 2010-04-15
AU2009301994A1 (en) 2010-04-15
CA2739246A1 (en) 2010-04-15
ZA201103240B (en) 2011-12-28
US9622977B2 (en) 2017-04-18
EP2349221A4 (en) 2013-03-27
KR20110069150A (ko) 2011-06-22
JP2012505203A (ja) 2012-03-01
EP2349221A2 (en) 2011-08-03
US20110244034A1 (en) 2011-10-06
MX2011003749A (es) 2011-09-01
WO2010041279A4 (en) 2010-09-10
BRPI0914080A2 (pt) 2015-10-27

Similar Documents

Publication Publication Date Title
IL210590A0 (en) Progestin-cotaining drug delivery system
ZA201002014B (en) Drug delivery system
ZA201103240B (en) Sustained release drug delivery system
EP2401012A4 (en) ACTIVE RELEASE SYSTEM
PT2398500T (pt) Sistema de entrega de medicamentos à base de glutationas
GB2442875B (en) Regulated drug delivery system
IL207366A0 (en) Drug delivery system with wireless nonitor
EP2299989A4 (en) STERILIZED TRANSDERMAL DRUG DELIVERY SYSTEM
IL212357A0 (en) Sustained drug delivery system
ZA201104620B (en) Zaleplon gastroretentive drug delivery system
PL2219603T3 (pl) Układ transdermalnego dostarczania
EP2213274A4 (en) DRUG DELIVERY SYSTEM, AND DRUG DELIVERY DEVICE
EP2178598A4 (en) IONTOPHORETIC DRUG DISTRIBUTION SYSTEM
IL214099A0 (en) Conjugate based systems for controlled drug delivery
GB0707928D0 (en) Delivery system
IL212767A (en) Device for administering drugs
IL206927A0 (en) Drug delivery system with stabilising effect
EP2506909A4 (en) ACTIVE RELEASE DEVICE
PL2437736T3 (pl) Systemy dostarczania leków
IL213577A0 (en) Drug delivery device
EP2319503A4 (en) DRUG DELIVERY VECTOR
IL212603A0 (en) Combined drug administration
ZA201006517B (en) Estradiol-containing drug delivery system
GB0817486D0 (en) Delivery system
GB0709545D0 (en) Regulated drug delivery system